- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cardiol Therapeutics: A Leader in Research and Commercial Development of Pharmaceutical Cannabidiol Products and Targeted Therapies for Heart Failure and Cancer
Cardiol Therapeutics Inc. (TSX:CRDL) has launched its campaign on the Investing News Network’s Life Science and Technology channels.
Cardiol Therapeutics Inc. (TSX:CRDL) has launched its campaign on the Investing News Network’s Life Science and Technology channels.
Cardiol is a biotechnology company focused on developing proprietary formulations that will treat some of the most life-threatening diseases in the western world. The Company is investigating targeting drugs to the heart to treat diastolic heart failure, including the use of highly purified pharmaceutically-manufactured cannabidiol (CBD).
Cardiol is developing unique manufacturing expertise in the production of pharmaceutical cannabinoids in support of its nanotherapeutics program in heart failure. With this goal in mind, the company has formed exclusive partnerships with Noramco and Dalton Pharma Services, both of which are FDA-certified and working under GMP standards, to manufacture CBD at >99.5% purity and less than 10 ppm THC. These companies have been instrumental in developing Cardiol’s pharmaceutical CBD products and in working to produce them at scale. Through these partnerships, Cardiol plans to develop and commercialize one of the most advanced formulations of pharmaceutical CBD during 2019, leading a market that is now estimated to exceed $600 million in Canada alone.
Cardiol Therapeutics’ company highlights include the following:
- Implementing nanotechnologies to deliver CBD and other anti-inflammatory drugs for the treatment of diastolic heart failure.
- Commercializing one of the most advanced formulations of pharmaceutical cannabidiol at >99.5% purity and less than 10 ppm THC during 2019 – a market estimated to exceed $600 million in Canada alone.
- Research programs at the University of Alberta, the Houston Methodist DeBakey Heart & Vascular Center, and TecSalud del Tecnológico de Monterrey, Mexico.
- Developing a combination therapy of cannabinoids and cell-based immunotherapies to improve the treatment of GBM.
- Exclusive partnerships with Dalton Pharma Services and Noramco.
- Management holds approximately 35 percent of the Company’s shares.
Latest News
Cardiol Therapeutics Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.